The stock is holding a support level at 50 cents. A thinly traded stock with a low float, SBFM can move rapidly in either direction. Technical traders will be watching for volume to accompany buying pressure to see if a test of resistance at 75 cents is in the future for this junior biotech. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts Let us hear your thoughts below:
It’s easy to forget that, in spite of periodic frustrations and disappointments, very real progress has been and continues to be made in the war against cancer. Decades of research have given us a much better understanding of how cancer operates at the cellular level. Developments in cancer prevention, screening, and therapy have saved millions of lives. Although there are still 1.5 million new cases of cancer diagnosed in the U.S. every year, the country now also has at least 11 million survivors of various types of cancer. But it’s important to remember that virtually all types of cancer are…
When Sunshine Biopharma, a development stage pharmaceutical company focused on cancer treatments, recently announced successful test results for its lead compound, Adva-27a, it represented one of several important milestones being met on the drug’s anticipated fast-track path to approval as a vital weapon in fighting particular forms of aggressive cancers. The latest study measured the ability of Adva-27a to inhibit the activity of Topoisomerase II (Top2) cancer growth enzyme, and results showed that the new drug is an excellent inhibitor, requiring a concentration of only 13.7 micromolar Adva-27a to inhibit 50% of the enzyme’s activity. Topoisomerase II is overproduced in…
A drug which could fill a major gap in the treatment of aggressive cancers has been developed by Sunshine Biopharma, a development stage pharmaceutical company focused on drugs for the treatment of various forms of cancer. The company’s lead compound, Adva-27a, has been shown to be remarkably effective in dealing with the Topoisomerase II (Top2) gene, which is responsible for the production of Top2, associated with breast, prostate, colon, lung, stomach, and ovarian cancer. Aggressive cancer cells produce too much Top2, and there are currently no satisfactory therapies for Top2 positive patients. The demonstrated effectiveness of Sunshine’s Adva-27a is seen…
Sunshine Biopharma, Inc. is focused on the research, development and commercialization of drugs designed to treat various forms of cancer. The Company’s lead compound, Adva-27a, is a multi-purpose anti-tumor compound currently in preclinical stage with plans to conduct Phase I clinical trials at the Segal Cancer Centre of the Jewish General Hospital, one of McGill University’s Hospital Centers located in Montreal, Canada. Almost 1.5 million new cases of cancer are diagnosed in the U.S. each year, according to the American Cancer Society. Virtually all cancer types are either aggressive at the onset or become aggressive over time. There are two…
Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the treatment of various forms of cancer, announced earlier today that it has completed a study in which the ability of Adva-27a, its lead compound, to inhibit the activity of Topoisomerase II was directly measured. Topoisomerase II (Top2) is an enzyme that enables cancers to grow rapidly. In multi-drug resistant breast cancer, the gene that encodes Top2 has been found to be amplified as much as 1,000%, allowing these cancer cells to make tens of thousands of Top2 molecules. By inhibiting Topoisomerase II activity, Adva-27a would arrest the ability of…
